SAMe

Phase 3Small molecule

IIndiana University

SAMe is one of 79 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

CirrhosisActive, not recruiting

Alcoholic Fatty Liver DiseasePhase 3

Active, not recruiting

CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

SAMe

IIndiana University

Phase 3

1 2

Proamatine

Takeda

Preclinical

9 3

Crestor

AstraZeneca

Preclinical

2 4

Dobutrex

Eli Lilly

Preclinical

1 5

Azulfidine

Pfizer

Preclinical

1 6

HEPCLUDEX

Gilead

Preclinical

1 7

Farxiga

AstraZeneca

Preclinical

1 8

Thalomid

Bristol-Myers Squibb

Preclinical

1 9

Revia

Teva

Preclinical

1 10

Cipro

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Cirrhosis

NCT04250259

Clinical

Trials by Indication[1]

Treatment-resistant Bipolar Depression1 trial

A Trial of SAMe for Treatment-Resistant Bipolar Depression

Completed·MMclean Hospital·N/A·NCT00762268·23 enrolled

Alcoholic Fatty Liver Disease1 trial

Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group

Completed·AAbbott·Phase 3·NCT01754714·108 enrolled

Cirrhosis1 trial

SAMe Trial for Patients With Alcoholic Cirrhosis

Recruiting·IIndiana University·Phase 2·NCT04250259·196 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAMe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAMe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAMe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIndiana University

SAMe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Treatment-resistant Bipolar Depression1 trial

Alcoholic Fatty Liver Disease1 trial

Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News